Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
BJD, 2023.
Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Lunt M, Smith CH, Griffiths, CEM; BADBIR Study Group
Read publication: BJD
Related
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study...
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000...
Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prosp...
0 Comments